

Haematologica  
HAEMATOL/2017/169326  
Version 3

Bortezomib as a new therapeutic approach for blastic plasmacytoid  
dendritic cell neoplasm

Laure Philippe, Adam Ceroi, Elodie Bôle-Richard, Alizée Jenvrin,  
Sabeha Biichle, Sophie Perrin, Samuel Limat, Francis Bonnefoy, Eric  
Deconinck, Philippe Saas, Francine Garnache-Ottou, and Fanny  
Angelot-Delettre

Disclosures: none

Contributions: Laure Philippe, Fanny Angelot-Delettre, Philippe Saas, and Francine Garnache-Ottou designed the study, and/or analyzed the data, and/or wrote the manuscript; Laure Philippe, Adam Ceroi, Alizee Jenvrin, Fanny Angelot-Delettre, Sabeha Biichle, and Francine Garnache-Ottou performed and/or validated experiments. Elodie Bole-Richard performed and/or validated news experiments for revised manuscript. Laure Philippe, Adam Ceroi, Fanny Angelot-Delettre, Francine Garnache-Ottou, Alizee Jenvrin and Francis Bonnefoy and Elodie Bole-Richard performed and/or validated mice experiments. Eric Deconinck was involved directly in the care of patients and/or sample procurement; Laure Philippe and Fanny Angelot-Delettre performed statistical analysis; Sophie Perrin et Samuel Limat provided essential reagent bortezomib and others therapeutics; all authors read and approved the final version of the manuscript.